125 related articles for article (PubMed ID: 22844376)
1. In vitro and in vivo antitumor effects of the recombinant immunotoxin IL6(T23)-PE38KDEL in multiple myeloma.
Guo DJ; Han JS; Li YS; Liu ZS; Lu SY; Ren HL
Oncol Lett; 2012 Aug; 4(2):311-318. PubMed ID: 22844376
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo studies of antitumor effects of the recombinant immunotoxin MSH-PE38KDEL on melanoma.
Hui Q; Ma J; Song J; Liu Z; Ren H; Jiang W; Wang Y; Xu Y; Guo D; Zhang X; Lu S
Neoplasma; 2014; 61(4):392-400. PubMed ID: 25027740
[TBL] [Abstract][Full Text] [Related]
3. Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy.
Chandramohan V; Bao X; Keir ST; Pegram CN; Szafranski SE; Piao H; Wikstrand CJ; McLendon RE; Kuan CT; Pastan IH; Bigner DD
Clin Cancer Res; 2013 Sep; 19(17):4717-27. PubMed ID: 23857604
[TBL] [Abstract][Full Text] [Related]
4. Recombinant heregulin-Pseudomonas exotoxin fusion proteins: interactions with the heregulin receptors and antitumor activity in vivo.
Yang D; Kuan CT; Payne J; Kihara A; Murray A; Wang LM; Alimandi M; Pierce JH; Pastan I; Lippman ME
Clin Cancer Res; 1998 Apr; 4(4):993-1004. PubMed ID: 9563895
[TBL] [Abstract][Full Text] [Related]
5. Purification and characterization of IL6-PE4E, a recombinant fusion of interleukin 6 with Pseudomonas exotoxin.
Kreitman RJ; Pastan I
Bioconjug Chem; 1993; 4(6):581-5. PubMed ID: 8305530
[TBL] [Abstract][Full Text] [Related]
6. Treatment of hepatocellular carcinoma in mice with PE38KDEL type I mutant-loaded poly(lactic-co-glycolic acid) nanoparticles conjugated with humanized SM5-1 F(ab') fragments.
Gao J; Kou G; Chen H; Wang H; Li B; Lu Y; Zhang D; Wang S; Hou S; Qian W; Dai J; Zhao J; Zhong Y; Guo Y
Mol Cancer Ther; 2008 Oct; 7(10):3399-407. PubMed ID: 18852143
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effects of interleukin 6-Pseudomonas exotoxin chimeric molecules against the human hepatocellular carcinoma, PLC/PRF/5 in mice.
Siegall CB; Kreitman RJ; FitzGerald DJ; Pastan I
Cancer Res; 1991 Jun; 51(11):2831-6. PubMed ID: 1851660
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment.
Reiter Y; Pai LH; Brinkmann U; Wang QC; Pastan I
Cancer Res; 1994 May; 54(10):2714-8. PubMed ID: 8168102
[TBL] [Abstract][Full Text] [Related]
9. Treatment of hepatocellular carcinoma in a mouse xenograft model with an immunotoxin which is engineered to eliminate vascular leak syndrome.
Wang H; Song S; Kou G; Li B; Zhang D; Hou S; Qian W; Dai J; Tian L; Zhao J; Guo Y
Cancer Immunol Immunother; 2007 Nov; 56(11):1775-83. PubMed ID: 17431617
[TBL] [Abstract][Full Text] [Related]
10. Targeting IL-13Ralpha2-positive cancer with a novel recombinant immunotoxin composed of a single-chain antibody and mutated Pseudomonas exotoxin.
Kioi M; Seetharam S; Puri RK
Mol Cancer Ther; 2008 Jun; 7(6):1579-87. PubMed ID: 18566228
[TBL] [Abstract][Full Text] [Related]
11. [Molecular design and construction of IL6D24-PE40KDEL, a novel recombinant interleukin6-pseudomonas exotoxin fusion protein, having targeted cytotoxicity for leukemias expressing interleukin6 receptors].
Zheng LY; Xi YZ; Kong FH; Cui JW; Liang F; Liu N; Sun YY; Guo SQ
Zhonghua Yi Xue Za Zhi; 2003 Jul; 83(14):1246-50. PubMed ID: 12930640
[TBL] [Abstract][Full Text] [Related]
12. Construction and recombinant expression of Pseudomonas aeruginosa truncated exotoxin A in Escherichia coli.
Qaiser H; Aslam F; Iftikhar S; Farooq A
Cell Mol Biol (Noisy-le-grand); 2018 Jan; 64(1):64-69. PubMed ID: 29412796
[TBL] [Abstract][Full Text] [Related]
13. Construction and expression of novel immunotoxin cpIL-4(13D)-PE38KDEL with increased activity.
Cui JX; Ji JF; Lv AG; Wu WF
Biochemistry (Mosc); 2005 Jan; 70(1):62-8. PubMed ID: 15701050
[TBL] [Abstract][Full Text] [Related]
14. PE38KDEL-loaded anti-HER2 nanoparticles inhibit breast tumor progression with reduced toxicity and immunogenicity.
Gao J; Kou G; Wang H; Chen H; Li B; Lu Y; Zhang D; Wang S; Hou S; Qian W; Dai J; Zhao J; Zhong Y; Guo Y
Breast Cancer Res Treat; 2009 May; 115(1):29-41. PubMed ID: 18481173
[TBL] [Abstract][Full Text] [Related]
15. Interleukin 4 receptor-directed cytotoxin therapy for human head and neck squamous cell carcinoma in animal models.
Strome SE; Kawakami K; Alejandro D; Voss S; Kasperbauer JL; Salomao D; Chen L; Maki RA; Puri RK
Clin Cancer Res; 2002 Jan; 8(1):281-6. PubMed ID: 11801570
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic activity of chimeric toxins containing the epidermal growth factor-like domain of heregulins fused to PE38KDEL, a truncated recombinant form of Pseudomonas exotoxin.
Kihara A; Pastan I
Cancer Res; 1995 Jan; 55(1):71-7. PubMed ID: 7805044
[TBL] [Abstract][Full Text] [Related]
17. Recombinant toxins containing human granulocyte-macrophage colony-stimulating factor and either pseudomonas exotoxin or diphtheria toxin kill gastrointestinal cancer and leukemia cells.
Kreitman RJ; Pastan I
Blood; 1997 Jul; 90(1):252-9. PubMed ID: 9207460
[TBL] [Abstract][Full Text] [Related]
18. A new scfv-based recombinant immunotoxin against EPHA2-overexpressing breast cancer cells; High in vitro anti-cancer potency.
Rezaie E; Amani J; Bidmeshki Pour A; Mahmoodzadeh Hosseini H
Eur J Pharmacol; 2020 Mar; 870():172912. PubMed ID: 31926992
[TBL] [Abstract][Full Text] [Related]
19. Cell-specific toxicity of a chimeric protein composed of interleukin-6 and Pseudomonas exotoxin (IL6-PE40) on tumor cells.
Siegall CB; Nordan RP; FitzGerald DJ; Pastan I
Mol Cell Biol; 1990 Jun; 10(6):2443-7. PubMed ID: 2160579
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-4 receptor expression on AIDS-associated Kaposi's sarcoma cells and their targeting by a chimeric protein comprised of circularly permuted interleukin-4 and Pseudomonas exotoxin.
Husain SR; Gill P; Kreitman RJ; Pastan I; Puri RK
Mol Med; 1997 May; 3(5):327-38. PubMed ID: 9205948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
